| 标题 |
[求助补充材料]
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet HIV 作者:Jean‐Michel Molina; Douglas Ward; Indira Brar; Anthony Mills; Hans‐Jürgen Stellbrink; et al 出版日期:2018-06-18 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)